Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies

Nausicaa Clemente; Benedetta Ferrara; Casimiro Luca Gigliotti; Elena Boggio; Maria Teresa Capucchio; Elena Biasibetti; Davide Schiffer; Marta Mellai; Laura Annovazzi; Luigi Cangemi; Elisabetta Muntoni; Gianluca Miglio; Umberto Dianzani; Luigi Battaglia; Chiara Dianzani

doi:10.3390/ijms19020255

Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies

Nausicaa Clemente, Benedetta Ferrara, Casimiro Luca Gigliotti, Elena Boggio, Maria Teresa Capucchio, Elena Biasibetti, Davide Schiffer, Marta Mellai, Laura Annovazzi, Luigi Cangemi, Elisabetta Muntoni, Gianluca Miglio, Umberto Dianzani, Luigi Battaglia, Chiara Dianzani

Dipartimento di Scienze della Salute

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Aim: To develop an innovative delivery system for temozolomide (TMZ) in solid lipid nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma. Materials and Methods: SLN-TMZ was obtained through fatty acid coacervation. Its pharmacological effects were assessed and compared with free TMZ in in vitro and in vivo models of melanoma and glioblastoma. Results: Compared to the standard free TMZ, SLN-TMZ exerted larger effects, when cell proliferation of melanoma cells, and neoangiogeneis were evaluated. SLN-TMZ also inhibited growth and vascularization of B16-F10 melanoma in C57/BL6 mice, without apparent toxic effects. Conclusion: SLN could be a promising strategy for the delivery of TMZ, allowing an increased stability of the drug and thereby its employment in the treatment of aggressive malignacies.

Lingua originale	Inglese
Numero di articolo	255
Rivista	International Journal of Molecular Sciences
Volume	19
Numero di pubblicazione	2
DOI	https://doi.org/10.3390/ijms19020255
Stato di pubblicazione	Pubblicato - feb 2018

Accesso al documento

10.3390/ijms19020255

Altri file e collegamenti

Link to publication in Scopus

Cita questo

Clemente, N., Ferrara, B., Gigliotti, C. L., Boggio, E., Capucchio, M. T., Biasibetti, E., Schiffer, D., Mellai, M., Annovazzi, L., Cangemi, L., Muntoni, E., Miglio, G., Dianzani, U., Battaglia, L., & Dianzani, C. (2018). Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies. International Journal of Molecular Sciences, 19(2), Articolo 255. https://doi.org/10.3390/ijms19020255

@article{baf3441457114a5c9489cf5132779a77,

title = "Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies",

abstract = "Aim: To develop an innovative delivery system for temozolomide (TMZ) in solid lipid nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma. Materials and Methods: SLN-TMZ was obtained through fatty acid coacervation. Its pharmacological effects were assessed and compared with free TMZ in in vitro and in vivo models of melanoma and glioblastoma. Results: Compared to the standard free TMZ, SLN-TMZ exerted larger effects, when cell proliferation of melanoma cells, and neoangiogeneis were evaluated. SLN-TMZ also inhibited growth and vascularization of B16-F10 melanoma in C57/BL6 mice, without apparent toxic effects. Conclusion: SLN could be a promising strategy for the delivery of TMZ, allowing an increased stability of the drug and thereby its employment in the treatment of aggressive malignacies.",

keywords = "Melanoma, SLN, Temozolomide",

author = "Nausicaa Clemente and Benedetta Ferrara and Gigliotti, {Casimiro Luca} and Elena Boggio and Capucchio, {Maria Teresa} and Elena Biasibetti and Davide Schiffer and Marta Mellai and Laura Annovazzi and Luigi Cangemi and Elisabetta Muntoni and Gianluca Miglio and Umberto Dianzani and Luigi Battaglia and Chiara Dianzani",

note = "Publisher Copyright: {\textcopyright} 2018 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2018",

month = feb,

doi = "10.3390/ijms19020255",

language = "English",

volume = "19",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

Clemente, N, Ferrara, B, Gigliotti, CL, Boggio, E, Capucchio, MT, Biasibetti, E, Schiffer, D, Mellai, M, Annovazzi, L, Cangemi, L, Muntoni, E, Miglio, G, Dianzani, U, Battaglia, L & Dianzani, C 2018, 'Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies', International Journal of Molecular Sciences, vol. 19, n. 2, 255. https://doi.org/10.3390/ijms19020255

TY - JOUR

T1 - Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies

AU - Clemente, Nausicaa

AU - Ferrara, Benedetta

AU - Gigliotti, Casimiro Luca

AU - Boggio, Elena

AU - Capucchio, Maria Teresa

AU - Biasibetti, Elena

AU - Schiffer, Davide

AU - Mellai, Marta

AU - Annovazzi, Laura

AU - Cangemi, Luigi

AU - Muntoni, Elisabetta

AU - Miglio, Gianluca

AU - Dianzani, Umberto

AU - Battaglia, Luigi

AU - Dianzani, Chiara

PY - 2018/2

Y1 - 2018/2

N2 - Aim: To develop an innovative delivery system for temozolomide (TMZ) in solid lipid nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma. Materials and Methods: SLN-TMZ was obtained through fatty acid coacervation. Its pharmacological effects were assessed and compared with free TMZ in in vitro and in vivo models of melanoma and glioblastoma. Results: Compared to the standard free TMZ, SLN-TMZ exerted larger effects, when cell proliferation of melanoma cells, and neoangiogeneis were evaluated. SLN-TMZ also inhibited growth and vascularization of B16-F10 melanoma in C57/BL6 mice, without apparent toxic effects. Conclusion: SLN could be a promising strategy for the delivery of TMZ, allowing an increased stability of the drug and thereby its employment in the treatment of aggressive malignacies.

AB - Aim: To develop an innovative delivery system for temozolomide (TMZ) in solid lipid nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma. Materials and Methods: SLN-TMZ was obtained through fatty acid coacervation. Its pharmacological effects were assessed and compared with free TMZ in in vitro and in vivo models of melanoma and glioblastoma. Results: Compared to the standard free TMZ, SLN-TMZ exerted larger effects, when cell proliferation of melanoma cells, and neoangiogeneis were evaluated. SLN-TMZ also inhibited growth and vascularization of B16-F10 melanoma in C57/BL6 mice, without apparent toxic effects. Conclusion: SLN could be a promising strategy for the delivery of TMZ, allowing an increased stability of the drug and thereby its employment in the treatment of aggressive malignacies.

KW - Melanoma

KW - SLN

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=85041018885&partnerID=8YFLogxK

U2 - 10.3390/ijms19020255

DO - 10.3390/ijms19020255

M3 - Article

SN - 1661-6596

VL - 19

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 2

M1 - 255

ER -

Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies

Abstract

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo